Let’s Work Together on Value Creation of Next-Gen Immune Therapies

At Pilatus Biosciences, we are developing next-generation immunotherapies that target metabolic checkpoints to reprogram the tumor microenvironment and address critical unmet needs in immune-resistant cancers, as well as immunological and metabolic diseases.

Our Business Development team is actively pursuing strategic partnerships—including regional co-development and licensing opportunities—to accelerate the advancement and global reach of our potential first-in-class therapies, PLT012 and PLT011.
We welcome collaboration with research institutions and biopharma partners who share our mission to deliver impactful, science-driven solutions for patients with life-threatening and chronic diseases.”